121 related articles for article (PubMed ID: 6332862)
1. Immunotherapy of lymphoid and nonlymphoid tumors with monoclonal anti-Lyt-1 antibodies.
Hollander N
J Immunol; 1984 Nov; 133(5):2801-5. PubMed ID: 6332862
[TBL] [Abstract][Full Text] [Related]
2. The immunotherapeutic effect of anti Lyt-1 antibodies on local and metastatic tumor growth.
Hollander N
Adv Exp Med Biol; 1985; 186():819-26. PubMed ID: 3876726
[TBL] [Abstract][Full Text] [Related]
3. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
4. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of murine leukemias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells.
Kirch ME; Hammerling U
J Immunol; 1981 Aug; 127(2):805-10. PubMed ID: 6788849
[TBL] [Abstract][Full Text] [Related]
6. The immunosuppressive effect of monoclonal anti-Lyt-1.1 antibodies in vivo.
Michaelides M; Hogarth PM; McKenzie IF
Eur J Immunol; 1981 Dec; 11(12):1005-12. PubMed ID: 6173235
[TBL] [Abstract][Full Text] [Related]
7. The functional association of Lyt antigens with lymphokine production.
Hollander N; Shepshalovich J
Immunology; 1985 Jan; 54(1):25-33. PubMed ID: 2579021
[TBL] [Abstract][Full Text] [Related]
8. The immunotherapeutic effects in tumor-bearing mice of Ly-6 monoclonal antibodies.
Lu L; Palladino MA; DeLeo AB
J Immunol; 1989 Jan; 142(2):719-25. PubMed ID: 2783443
[TBL] [Abstract][Full Text] [Related]
9. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
Evans R; Duffy T
J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
[TBL] [Abstract][Full Text] [Related]
10. A role for Lyt-2+ T cells in resistance to cutaneous leishmaniasis in immunized mice.
Farrell JP; Muller I; Louis JA
J Immunol; 1989 Mar; 142(6):2052-6. PubMed ID: 2784148
[TBL] [Abstract][Full Text] [Related]
11. In-vivo modulation of thymus-derived lymphocytes with monoclonal antibodies in mice. I. Effect of anti-Thy-1 antibody on the tissue distribution of lymphocytes.
Le Gros GS; Prestidge RL; Watson JD
Immunology; 1983 Dec; 50(4):537-46. PubMed ID: 6606612
[TBL] [Abstract][Full Text] [Related]
12. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
Henderson LA; Ciavarra R; Riblet R; Forman J
J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
[TBL] [Abstract][Full Text] [Related]
13. Regulatory role of T lymphocytes and NK cells in tumor allograft development.
Sobotková E; Nouza K
Neoplasma; 1993; 40(2):75-80. PubMed ID: 8350958
[TBL] [Abstract][Full Text] [Related]
14. Detection of a common antigen on murine B cells and Lyt-2+ T cells by a rat monoclonal antibody, 14D10.
Kung JT; Sharrow SO; Mage MG; Paul WE
J Immunol; 1982 Jul; 129(1):81-6. PubMed ID: 6806368
[TBL] [Abstract][Full Text] [Related]
15. Rat T lymphocyte antigens comparable with mouse Lyt-1 and Lyt-2,3 antigenic systems: characterization by monoclonal antibodies.
Matsuura A; Ishii Y; Yuasa H; Narita H; Kon S; Takami T; Kikuchi K
J Immunol; 1984 Jan; 132(1):316-22. PubMed ID: 6606669
[TBL] [Abstract][Full Text] [Related]
16. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
17. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
18. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
19. Capacity of purified unprimed Lyt-2+ cells to reject Ia- H-2-different tumor cells in the Winn assay.
Sprent J; Schaefer M
J Immunol; 1988 May; 140(9):2899-902. PubMed ID: 3258888
[TBL] [Abstract][Full Text] [Related]
20. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
